SH2D4A–HDGF Axis Mediates OTUD4’s Control of Ovarian Cancer Malignant Behavior

A Molecular “Brake” May Help Ovarian Cancer Cells Resist Their Own Most Dangerous Behaviors

Ovarian cancer cells may be controlled by a previously underappreciated molecular pathway that links protein recycling, cell growth and response to chemotherapy, according to a study published in the Journal of Translational Medicine. The research identifies a regulatory chain involving the proteins OTUD4, SH2D4A and HDGF, and suggests that this pathway could influence how aggressively ovarian tumors grow and how effectively they respond to cisplatin, one of the most widely used drugs in ovarian-cancer treatment. In laboratory experiments, increasing the amount of SH2D4A reduced cancer-cell proliferation and colony formation while making cells more sensitive to cisplatin. The findings also point toward a mechanism: SH2D4A appears to restrain the movement of hepatoma-derived growth factor, or HDGF, into the cell nucleus. Because the nucleus contains the genetic machinery that controls cell division and survival, blocking HDGF’s nuclear access may deprive ovarian cancer cells of a signal that helps them thrive.

The discovery matters because ovarian cancer is often diagnosed after it has spread beyond the ovaries, when surgery and chemotherapy become more difficult and recurrence is common. High-grade serous ovarian cancer, the disease model examined in the study, is particularly dangerous because tumor cells can adapt to treatment and acquire resistance to platinum-based drugs. Cisplatin works primarily by damaging DNA. Once inside a cell, the drug forms chemical links between DNA bases, creating lesions that interfere with replication and transcription. Cells that cannot repair the damage activate stress responses and may undergo apoptosis, a controlled form of cell death. Cancer cells, however, can survive by improving DNA repair, changing drug transport, altering cell-death pathways or activating growth-promoting signals. The new work does not establish a treatment for patients, but it adds a possible layer to this complex biology by showing that the abundance and location of SH2D4A and HDGF can alter the behavior of ovarian cancer cells in experimental systems.

The investigators began with OTUD4, a deubiquitinase associated with ovarian tumors. Deubiquitinases are enzymes that remove ubiquitin molecules from proteins. Ubiquitin is often described as a cellular disposal tag, but its functions are broader: attaching ubiquitin can change a protein’s stability, location, activity or interactions, depending on the type and arrangement of the ubiquitin chain. By reversing ubiquitination, deubiquitinases can influence signaling networks that govern proliferation, DNA damage responses and immune interactions. The researchers’ earlier work and proteomic analyses indicated that OTUD4 restrained malignant behavior and physically associated with SH2D4A, a protein containing an SH2 domain. SH2 domains commonly recognize phosphorylated tyrosine residues and help assemble signaling complexes, although the precise role of SH2D4A in ovarian cancer had not been established. Clinical tumor data further suggested that SH2D4A is expressed at relatively low levels in ovarian-cancer tissues, raising the possibility that loss of this protein removes a natural barrier to tumor progression.

To test that possibility, the team manipulated SH2D4A in two high-grade serous ovarian-cancer cell lines, OVCAR8 and CAOV3. Cells engineered to produce more SH2D4A divided less rapidly and formed fewer colonies in culture. Colony-formation assays are commonly used to measure the ability of individual cancer cells to survive, proliferate and generate larger cell populations over time; a reduction in colonies indicates that the cells’ long-term reproductive capacity has been weakened. Flow-cytometry experiments provided additional evidence that increasing SH2D4A changed cell-cycle or cell-death behavior in a direction consistent with reduced malignancy. When the researchers knocked down SH2D4A, using molecular tools to lower its expression, the pattern reversed: ovarian-cancer cells displayed increased malignant characteristics. Together, the complementary gain- and loss-of-function experiments strengthened the case that SH2D4A is not merely correlated with tumor behavior but contributes directly to it, at least in the cellular models used.

The study also connected SH2D4A to cisplatin sensitivity. When SH2D4A was overexpressed, ovarian-cancer cells responded more strongly to cisplatin, and the same trend was observed in mice carrying OVCAR8 tumors. In practical terms, tumors with more SH2D4A were less able to maintain growth under treatment than tumors lacking the protein. The result is potentially important because chemotherapy response is not determined by drug exposure alone; it depends on whether a cancer cell interprets DNA damage as a signal to stop dividing and die. SH2D4A could influence one or more of those downstream decisions. However, the experiments do not show that SH2D4A directly binds cisplatin or repairs DNA lesions. Instead, they indicate that the protein changes the cellular state in a way that makes cisplatin’s damage more consequential. The mouse evidence is also an early preclinical step, not proof that restoring SH2D4A would be safe or effective in human patients.

A key experiment tied SH2D4A to OTUD4. Although OTUD4 had previously been associated with a less aggressive ovarian-cancer phenotype, reducing SH2D4A eliminated the beneficial effects of increasing OTUD4. This “dependency” experiment suggests that SH2D4A operates downstream of OTUD4 rather than functioning as an unrelated parallel signal. In a biological pathway, such an order can be inferred when changing an upstream regulator produces an effect that disappears after a downstream component is removed. The result supports a model in which OTUD4 helps maintain or activate SH2D4A, while SH2D4A then suppresses molecular events that promote tumor growth and drug resistance. The study does not fully resolve how OTUD4 controls SH2D4A. It remains unclear whether OTUD4 directly deubiquitinates SH2D4A, stabilizes it indirectly, alters its intracellular distribution or affects another protein that connects the two. Answering that question will be essential before the pathway can be targeted rationally.

The researchers next searched for proteins that might explain how SH2D4A exerts its effects. By intersecting SH2D4A-interacting proteins with factors linked to cisplatin response and ovarian cancer, they highlighted HDGF. Despite its name, hepatoma-derived growth factor is not restricted to liver tumors. It is a secreted and intracellular growth-associated protein that can participate in cell proliferation, survival, migration and tissue repair. Its location inside the cell is especially relevant. HDGF can enter the nucleus, where it may influence chromatin-associated processes and gene expression, helping create conditions favorable to continued cell division. In experiments using immunofluorescence and western blotting, increased SH2D4A was associated with lower levels of HDGF in the nucleus. Immunofluorescence allows researchers to visualize where proteins reside within cells, while western blotting measures protein abundance in separated cellular fractions or whole-cell extracts. The combined evidence indicated that SH2D4A affects HDGF’s intracellular distribution rather than simply changing a single bulk protein measurement.

The most direct test came when the team supplied cells with additional HDGF. Exogenous HDGF counteracted the effects of SH2D4A, restoring stronger proliferation and reducing the cell-death response associated with SH2D4A expression. This rescue experiment places HDGF functionally downstream of SH2D4A: if extra HDGF can override the growth-suppressing protein, then limiting HDGF activity or access to the nucleus is likely central to SH2D4A’s action. The proposed OTUD4–SH2D4A–HDGF axis therefore resembles a molecular relay. OTUD4 is positioned at the upstream regulatory level; SH2D4A acts as an inhibitory intermediary; and HDGF provides a downstream growth-associated signal whose nuclear translocation helps sustain malignant behavior. The exact physical interaction remains to be mapped in detail. The authors report that SH2D4A binds HDGF, but future work will need to determine which domains make contact, whether ubiquitination controls that interaction and what nuclear genes are altered when HDGF is excluded.

The findings could eventually inspire several therapeutic strategies, although each remains speculative. One approach would be to increase SH2D4A activity or stability in tumors where the protein is suppressed. Another would be to prevent HDGF from entering the nucleus, either by disrupting its interaction with SH2D4A-regulated transport machinery or by blocking the signals that drive its nuclear accumulation. A third possibility would be to use the pathway as a biomarker: ovarian tumors with low SH2D4A or high nuclear HDGF might be more likely to behave aggressively or respond poorly to cisplatin. Such applications require substantial validation. The current study used two cell lines and one tumor-bearing mouse model, and laboratory models cannot reproduce the genetic diversity, immune environment and treatment history of patients. The researchers will also need to test whether the axis operates in larger collections of human tumors, whether it predicts outcomes independently of established clinical factors and whether manipulating it enhances chemotherapy without damaging normal tissues. For now, the work offers a mechanistic clue rather than a clinical breakthrough: by linking OTUD4 to SH2D4A and showing that SH2D4A can restrain HDGF’s journey into the nucleus, it reveals a potential molecular brake that ovarian cancer cells may release as they become more aggressive and treatment-resistant.